An Overview on Covid 19 Pandemic and its Impact on Forensic Investigations

Ajay Sharma¹, Rajesh Singh² and RK Kumawat³*

¹Director, State Forensic Science Laboratory, India
²Assistant Director (Biology), State Forensic Science Laboratory, India
³Senior Scientific Officer (Sero/DNA), State Forensic Science Laboratory, India

Submission: August 19, 2020; Published: October 05, 2020

*Corresponding author: RK Kumawat, Senior Scientific Officer (Sero/DNA), State Forensic Science Laboratory, Rajasthan Jaipur 302016, India

Abstract

The novel corona virus or COVID 19, created a pandemic throughout the world due to its transmissibility, highly virulent nature and severe pathogenicity. It has been established that it transmits through liquid droplets during coughing, sneezing, loud speaking, and spitting out. As per the World Health Organization (WHO), the viral particles persist on the various surfaces up to 5 days depending upon the environmental conditions and nature of surfaces. These long-lasting persistence and airborne transmission of Corona viral particles impose serious threat for forensic investigators as well as for all the law enforcement agencies. In this article, we explore the impact of COVID 19 pandemic on forensic investigation at the scene of a crime, sample collection, transport, storage, and laboratory examination. This article also helps to understand the overview of the novel corona virus and to adopt the best biosafety practices by the forensic science community and other law enforcement agencies, which will help in the balancing to conduct the investigations and protection against novel viral infections by following the safety guidelines formulated by the concerned central and state government.

Keywords: COVID19; Forensic investigation; WHO; Legal system; Safety guideline

Abbreviations: SARS: Severe Acute Respiratory Syndrome; ORF: Open Reading Frame; CD4: Cluster Differentiation T cells 4; ICMR: Indian Council of Medical Research; NIV: National Institute of Virology; SOP: Standard Operating Procedure; BSL2: Biosafety Level 2; PPE: Personal Protective Equipment

Introduction

Origin and spread of COVID 19

The aggressive and highly transmissible nature and severe pathogenicity of the novel Severe Acute Respiratory Syndrome (SARS) - coronavirus-2 (SARS-CoV-2) created the global pandemic situation, is also referred to as novel corona virus (2019-nCoV) or SARS-CoV-2 or COVID 19 [1]. The SARS-CoV-2 or COVID 19 originated from Wuhan city of China in December 2019. Several initial patients suffering from pneumonia have visited the wet seafood market of Wuhan city of China and later on, molecular diagnosis of these human patients showed the presence of novel corona virus. This novel virus first described as 2019-nCoV and World Health Organization (WHO) renamed it COVID 19 and due to an exponential increase of confirmed COVID patients WHO declared it, a public health emergency of international concern on 30th January 2020 [2]. After this declaration of international public health emergency, a pandemic situation was created across the world and all the countries focused their total attention to this critical condition to break the chain of spreading of this virus by adopting various safety measures and formulated the safety guidelines at the national level along with awareness and educating the people. As on August 19th, 2020 as per WHO, global cumulative COVID 19 cases are 21,756,357 and 771,635 deaths have been reported. Across the globe, the United State of America (USA) has the highest number of COVID 19 cases and deaths, i.e. 5,354,013 and 168,999 respectively, and community transmission stage. Brazil comes in the second position with the number of COVID 19 cases and deaths, i.e. 3,340,197 and 107,852 respectively. India is the second most populated country aligned with diversified populations residing in urban and rural areas of the country [3,4]. Across the globe, India is the 3rd country to the total number of COVID 19 confirmed cases, deaths and active Covid 19 cases i.e. 2766410, 53334 and 676,528 (Figure 1) & (Table 1).
### Table 1: COVID19 data of Indian states and Union Territories as on August 19th, 2020 [Data source: https://covidindia.org]

| State/Union Territories          | Number of Confirmed Cases | Number of Recovered Cases | Number of Deaths |
|----------------------------------|---------------------------|---------------------------|-----------------|
| Andaman and Nicobar Islands      | 2529                      | 1421                      | 30              |
| Andhra Pradesh                   | 306261                    | 218311                    | 2820            |
| Arunachal Pradesh                 | 2875                      | 1949                      | 5               |
| Assam                            | 82201                     | 58294                     | 203             |
| Bihar                            | 109875                    | 80740                     | 558             |
| Chandigarh                       | 2305                      | 1243                      | 30              |
| Chhattisgarh                      | 16726                     | 10847                     | 158             |
| Dadar & Nagar Haveli; Daman & Diu| 1959                      | 1519                      | 2               |
| Delhi                            | 154741                    | 139447                    | 4226            |
| Goa                              | 12333                     | 8356                      | 116             |
| Gujarat                          | 80802                     | 63703                     | 2820            |
| Haryana                          | 48971                     | 41333                     | 557             |
| Himachal Pradesh                  | 4235                      | 2923                      | 19              |
| Jammu and Kashmir                | 29326                     | 21886                     | 561             |
| Jharkhand                        | 25333                     | 15709                     | 265             |
| Karnataka                        | 240948                    | 156949                    | 4210            |
| Kerala                           | 47898                     | 31390                     | 175             |
| Ladakh                           | 2010                      | 1395                      | 14              |
| Lakshadweep                      | 0                         | 0                         | 0               |
| Madhya Pradesh                   | 47375                     | 35713                     | 1141            |
| Maharashtra                      | 615477                    | 437870                    | 20999           |
| Manipur                          | 4765                      | 2789                      | 18              |
| Meghalaya                        | 1454                      | 683                       | 6               |
| Mizoram                          | 815                       | 372                       | 0               |
| Nagaland                         | 3520                      | 1664                      | 8               |
| Odisha                           | 64533                     | 45315                     | 415             |
| Puducherry                       | 8396                      | 4909                      | 123             |
| Punjab                           | 34400                     | 21762                     | 898             |
| Rajasthan                        | 63977                     | 48887                     | 898             |
| Sikkim                           | 1207                      | 755                       | 2               |
| Tamil Nadu                       | 349654                    | 289787                    | 6007            |
| Telangana                        | 93937                     | 72202                     | 711             |
| Tripura                          | 7424                      | 5404                      | 62              |
| Uttar Pradesh                    | 162434                    | 109607                    | 2585            |
| Uttarakhand                      | 12961                     | 8724                      | 164             |
| West Bengal                      | 122753                    | 92690                     | 2528            |
| **Total**                        | **2766410**               | **2036548**               | **53334**       |
A general account of COVID 19

The COVID 19 or SARS-CoV-2 virus genome is 30,000 base pairs (bp) size, which encodes large non-structural poly-protein, which further cleaved into 15/16 proteins; 5 accessory proteins i.e. Open Reading Frame (ORF) 3a, ORF6 to ORF9; and 4 structural proteins i.e. spike glycoprotein, membrane glycoprotein, envelope protein and nucleocapsid protein which are essential for the structure and infectious nature of COVID 19 [5-7]. COVID 19 or SARS-CoV-2 virus is the 7th member of corona virus (CoVs) family which infects the human. The other six members of CoVs family are HCoV-229E, HCoV NL63, HCoV-OC43, HCoV-HKU1 which are causing agents of common cold; and SARS-CoV and MERS-CoV are causing agents of severe pneumonia [8]. The surface spike glycoprotein of Corona virus binds with Angiotensin-Converting Enzyme 2 (ACE2) receptors, which are found in the lower part of the respiratory tract of the humans [9,3]. It is established that novel SARS-CoV-2 or COVID 19 has 10-20 times more affinity than the SARS-CoV spike proteins to bind with the human ACE2 receptor, which is the cause of high transmission rates [10,11]. After the entry of the virus into the alveolar epithelial cell of the respiratory system, SARS-CoV-2 replicates in the host cell and undertakes the host cell regulation, which causes severe triggering of immune response resulting in hypercytokinemia and pulmonary tissue damage and ultimately reflected into Acute Respiratory Distress Syndrome (ARDS) and multiple organ failure [12-15]. In the COVID 19 infection immune system weakened by decreased and/or functionally exhausted total T cells, Cluster Differentiation T cells 4 (CD4), and Cluster Differentiation T cells 8(CD8) [2].

Transmission, incubation, and susceptibility of COVID19

The novel COVID19, sporadically transmitting virus among the humans through the respiratory tract via liquid droplets during coughing, sneezing, loud speaking, spitting out, and close contact in the environment with high aerosol concentrations. Direct and indirect contact of infectious agents or surfaces to the mucus membranes of nose, mouth, and eyes are the most common entry route of COVID19 into the body [16,17]. Recent studies showed that the digestive tract is also a potential route of COVID 19 [18]. After entrance the viral particles in the human body, it incubates in the body with the mean incubation period...
ranged from 2-14 days with the symptomatic and asymptomatic condition and both categories of infected people can act as a super spreader of the various [19,20]. The symptom of the infection of this virus expressed or not depends on the health condition of an individual. It has been established that the lower immunity people, pregnant women, newborn children, and old age people are more susceptible to this infection [21,22,15].

**Confirmatory test of COVID 19**

In the country, the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV) jointly formulated a standard operating procedure (SOP) for the detection of novel corona virus 2019-nCoV in suspected person using the rRT-PCR assay. In this assay TaqMan fluorogenic probe-based chemistry that uses the 5’ nuclease activity of Taq DNA polymerase and enables the detection of specific PCR as it accumulates during PCR cycle. ORF 1b, RdRp gene assay, E gene Assay, and N gene assay have been recommended by ICMR- NIV. Primers and probes used for E gene and RNaSe assay are listed in Table 2. (https://www. who.int/health-topics/coronavirus/laboratorydiagnostics-for-novel-coronavirus).

**Discussion**

**Impact of COVID 19 on the forensic investigation**

It has been established that the novel corona virus rapidly transmits through liquid droplets spread during coughing, sneezing, and loud speaking, spitting which supports the airborne transmission [23]. The viral particles found in body fluids, viscera of COVID19 positive individuals; and long-lasting persistence of viral particles on various surfaces are the serious concern for forensic community, police, and legal system. In this pandemic situation, many forensic science laboratories as being remain fully functional and have significant role in the criminal investigation system with the inception of crime to the conviction of criminals in the court of law, along with several challenges. The inevitable challenges for the forensic fraternity from the scientific investigation at the scene of a crime, laboratory examination and testimony in the court of law; that need to be addressed to adopt best practices with the self-protection from the novel viral infection as well as deal with the qualitative forensic examination of evidential materials [23-25].

**Sample collection and transport to the forensic laboratory**

At the scene of crime, scientific evidential material might be subjected to novel viral infection due to COVID 19 infected victim, suspect, or other related individuals. The biological fluid, i.e. blood, semen, saliva, tissues, and other evidential exhibits found at the scene of a crime, might be prone to novel viral infection, leads the risk of direct infection to the forensic experts [23]. Therefore, forensic experts must follow the safety guidelines formulated by the national level and must wear the Personal Protective Equipment (PPE) kit, i.e. standard mask, gloves, face shield, body cover (full sleeve gown). The evidential exhibits must be collected according to standard procedure formulated by the laboratory; additionally, the sealed packet must be externally covered in the water-resistant outer covering to sanitize the packet at every stage of handling. Similarly, the samples are taken during the medico-legal examination of the victim and suspect of sexual assault cases, during post-mortem examination, etc., the sample must be collected according to standard procedure, sealed with additional outer water resistant surface to sanitize the samples at every handling stage. If the victim, suspects, and deceased have been confirmed of SARS-CoV-2 infection, then their samples must be labeled properly and sealed in such a way to sanitize the outer surface every step of handling. Our laboratory has passed a guideline for the samples forwarded to the laboratory, in which it is stated that the forwarding letter along with other relevant letter must be packed in the sterilized zip-lock polybag, and its outer surface should be sanitized before sending to the laboratory and should be sanitized again at the time of receiving. The samples must be carried with the special messenger with PPE kits and sanitized before at every handling step. A competent authority should issue a certificate of proper sanitization of the samples before sending to the laboratory. This will lead an effective step to reduce the risk factor of this novel viral infection in the forensic community during this pandemic situation.

**Laboratory examination of the COVID 19 suspected samples**

WHO recommended that every sample to be analyzed in the laboratory and collected during this pandemic must be considered as a potential source of infection? This assumption must be followed at the time of forensic examination of the evidential exhibits, and the laboratory should be followed in a Biosafety level 2 laboratory working conditions, and all the laboratory personnel must treat their work at a high risk of infection. The case opening room of the laboratory must be disinfected with extensive care. The biosafety cabinet II must be used for opening the case and all the downstream examinations. This practice leads to a low risk of air born transmission of the SARS-CoV-2 virus. Before the examination, preprocessing steps should be adopted in the examination, in which the sample must be handled with extra care, and before opening the packets sanitization of the outer surface of the packets must be assured. After the sampling for examination, the remnants of the samples must be discarded by following the recommendations of the Biosafety level 2 laboratory. Before the pandemic situation, the forensic samples were examined at the standard laboratory open benches without the use of special protective equipment’s. To prevent the cross infection among the laboratory personnel, social distancing at least 2 yards must be maintained and must follow the guideline formulated by the WHO, national, and state level. After the examination of forensic exhibits sealed properly additionally water resistance outer cover and sanitized before sending to the concerned authority. The
report must be sealed properly and kept in a zip-lock polybag, sanitized before sending it to the competent authority. It has been established that long period wearing of PPE kits create various problems, such as discomfort, the heat, loss of normal sense of smell, loss of tactile sensation, difficulties in hand movements, impaired visibility, stress, anxiety, and problems in verbal communication [21]. Keeping these challenges in the minds, the rotational duties for short duration must be followed by the administration in this pandemic situation. The laboratory work should be categorized into various groups and work responsibility must be undertaken according to the COVID 19 infection risk factors. The laboratory personnel who are above the age of 50 years or low immunity person and the pregnant women must be kept away from the high-risk zone. All the laboratory personnel must maintain proper social distance at least 2 yards and follow the guidelines formulated by WHO, National level, and State level. By rotational way crime scene must be an investigation along with extended care of handling the high-risk articles [26,27].

Conclusion

To prevent the spread of the novel SARS-CoV-2 virus, we must strictly follow the safety guidelines and use of PPE kit during the handling of infection-prone exhibits or sites. Routine forensic laboratories should extend their laboratory condition according to the Biosafety Level 2 (BSL2) laboratory. Rotational working conditions will lead to reducing the chance of risk factors for infection. This article will be helpful for the forensic community as well as other law enforcement agencies to understand the infectious nature, pathogenicity, rapid transmission, and challenges that arise during this pandemic situation and safety measures to be adopted during a forensic investigation.

Acknowledgement

Authors express their sincere thanks towards all the forensic scientist who are doing their duties in the era of Covid19 pandemic.

References

1. Gorbatenya AE, Baker SC, Barik RS, de Groot RJ, Gulyaeva AA (2020) The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCov and naming it SARS-CoV-2. Nature Microbiology 5(4): 536.
2. Sun J, He WT, Wang L, Lai A, Ji X, et al. (2020) COVID-19: epidemiology, evolution, and cross-disciplinary perspectives. Trends in Molecular Medicine 26(5): 483-495.
3. Tamang R, Thangaraj K (2012) Genomic view on the population of India. Investigative Genetics 3(1): 20.
4. Basu A, Mukherjee N, Roy S, Sengupta S, Banerjee S (2003) Ethnic India: a genomic view, with special reference to population and structure. Genome Research 13(10): 2277-2290.
5. Ramaiah A, Arumugaswami V (2020) Insights into cross-species evolution of novel human coronavirus 2019-nCoV and defining immune determinants for vaccine development. BioRxiv.
6. Wu A, Peng Y, Huang B, Ding X, Wang X, et al. (2020) Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host & Microbe 27(11): 325-328.
7. Chan JFW, Kok KH, Zhu Z, Chu H, To KKW, et al. (2020) Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging Microbes & Infections 9(1): 221-236.
8. Paules CI, Marston HD, Fauci AS (2020) Coronavirus infections-more than just the common cold. Jama 323(8): 707-708.
9. Kuba K, Imai Y, Rao S, Gao H, Guo E, et al. (2005) A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nature Medicine 11(8): 875-879.
10. Hui DS, Azhar EI, Madani TA, Ntoumi F, Kock R, et al. (2020) The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health: The latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of Infectious Diseases 91: 264-266.
11. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, et al. (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798): 270-273.
12. Villar J, Zhang H, Shitsky AS (2019) Lung repair and regeneration in ARDS: role of PECAM1 and Wnt signaling. Chest 155(3): 587-594.
13. Channappanavar R, Perlman S (2017) Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Seminars in Immunopathology 39(5): 529-539.
14. Wang H, Ma S (2008) The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. The American Journal of Emergency Medicine 26(6): 711-715.
15. Chen H, Guo J, Wang C, Luo F, Yu X, et al. (2020) Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet 395(10226): 809-815.
16. Lu C, Liu X, Jia Z (2020) 2019-nCoV transmission through the ocular surface must not be ignored. Lancet 395(10224): e39.
17. Xia J, Tong J, Liu M, Shen Y, Guo D (2020) Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. Journal of Medical Virology 92(6): 589-594.
18. Zhang H, Kang Z, Gong H, Xu D, Wang J, et al. (2020) The digestive system is a potential route of 2019-nCoV infection: a bioinformatics analysis based on single-cell transcriptomes. BioRxiv.
19. Backer JA, Klinkenberg D, Wallinga J (2020) Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-8 January 2020. Eurosurveillance 25(5): 2000662.
20. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, et al. (2020) The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Annals of Internal Medicine 172(9): 577-582.
21. Chen N, Zhou M, Dong X, Qu J, Gong F, et al. (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 395(10223): 507-513.
22. Huang C, Wang Y, Li X, Ren L, Zhao J, et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 395(10221): 497-506.
23. De Ungria MCA (2020) Forensic DNA testing during the SARS-CoV-2 pandemic. Forensic Science International: Genetics 102346.
24. Vidua RK, Choulsey VK, Bhargava DC, Kumar J (2020) Problems arising from PPE when worn for long periods. Medico-Legal Journal 0025817220935880.
25. Hanley B, Lucas SB, Youd E, Swift B, Osborn M (2020) Autopsy in suspected COVID-19 cases. Journal of Clinical Pathology 73(5): 239-242.

26. Diao B, Wang C, Tan Y, Chen X, Liu Y, et al. (2020) Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Frontiers in Immunology 11: 827.

27. Raj VS, Mou H, Smits SL, Dekkers DHW, Müller MA, et al. (2013) Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495(7440): 251-254.